Law requires disclosure of research bucks, gifts

May 2010
Clinical Trials Administrator;May2010, Vol. 8 Issue 5, p52
The article presents some details of the Physician Payment Sunshine Provision under the Patient Protection Affordable Care Act in the U.S. The provision requires the disclosure of all gifts and compensation made by pharmaceutical and biotech companies to physicians, as well as to researchers. Some of the information included in the disclosure are name, business address, physician specialty and drug samples. Items that are considered payment under the provision include gift, food, entertainment, travel or trip.


Related Articles

  • Statistically Insignificant Deaths: Disclosing Drug Harms to Investors (and Patients) Under SEC Rule 10b-5. Mocsary, George A. // George Washington Law Review;Dec2013, Vol. 82 Issue 1, p111 

    This Article, using statistical tools and theory in conjunction with more standard legal approaches, argues that pharmaceutical manufacturers should disclose all cases of illness or injury associated with their products because this data is material to patients and their doctors, and therefore...

  • Mission: Top Secret Disclosures.  // Health Information Compliance Alert;11/1/2010, Vol. 10 Issue 11, p81 

    The article discusses the provisions of health information disclosures under the U.S. Health Insurance Portability and Accountability Act (HIPAA). Attorney Bill Mandell, a partner with Pierce & Mandell in Boston, explains that there are several types of disclosures such as for the protection of...

  • Put Patients First in Clinical Trials. Brescia, Bonnie // Pharmaceutical Executive;Nov2000, Vol. 20 Issue 11, p138 

    Deals with patient recruitment in clinical studies. Discussion on weighing the risks and benefits of clinical trials; Challenge of protecting patient interests and acceleration of enrollment of participants in trials; What pharmaceutical companies must do to improve their research plans.

  • SOMEBODY'S WATCHING ME: PROTECTING PATIENT PRIVACY IN PRESCRIPTION HEALTH INFORMATION. Smith, Christopher R. // Vermont Law Review;Summer2012, Vol. 36 Issue 4, p931 

    The article discusses prescription information and a patient's right to privacy as of June 2012, focusing on the impact of the U.S. Supreme Court's ruling in the 2011 case Sorrell v. IMS Health Inc. which deals with Vermont's statutory ban against the sale or disclosure of information regarding...

  • Managed care update. Kellar, Dixie // MLO: Medical Laboratory Observer;Dec99, Vol. 31 Issue 12, p8 

    Presents an update on managed care in the U.S. as of December 1999. Results of a survey on the attitude of doctors toward falsifying documents to provide warranted care for patients; Risk of failure of small U.S. health maintenance organizations (HMO); Views of benefits and human resources...

  • Patient rights bill, key Medicare issues top health agenda in new Congress. Gatty, Bob // Dermatology Times;Jan1999, Vol. 20 Issue 1, p44 

    Focuses on regulatory developments in the United States affecting physicians for the month of January 1999. United States Congress' focus on patients' rights bill and medical care issues in 1999; Remarks from Bill Rigney, director of the American Academy of Dermatology (AAD), on the AAD's...

  • Massachusetts Enacts Pharmaceutical and Medical Device Disclosure Law.  // Venulex Legal Summaries;2008 Q3, following p4 

    The article focuses on the enactment of a marketing disclosure law that requires pharmaceutical and medical device makers to report information related to marketing activities with physicians and other health care providers by the Commonwealth of Massachusetts on August 10, 2008. It cites that a...

  • Industry funded patient information and the slippery slope to New Zealand. Toop, Les; Mangin, Dee // BMJ: British Medical Journal (International Edition);10/6/2007, Vol. 335 Issue 7622, p694 

    The authors reflect on the European parliament, which is considering proposals allowing the drug industry to have a much greater role in providing information to patients, with no restrictions on the type of media. The authors suggest that if the proposals are passed, European countries could...

  • Bayer faces potential fine over cholesterol lowering drug. Tuffs, Annette // BMJ: British Medical Journal (International Edition);8/25/2001, Vol. 323 Issue 7310, p415 

    Reports that German pharmaceutical company Bayer may be forced to pay a fine for withholding from the German authorities information on the drug's potentially fatal interaction with another drug. Withdrawal of the drug cerivastatin after deaths occurred in patients taking the drug; Assertion by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics